1Q23 Business Results

RemsimaⓇSC (1/2) ✓ Both RemsimaⓇ and RemsimaⓇSC's market share has increased in the entire European market M/S trend of CTHC's Infliximab products in Europe 33% 33% 33% 32% 30% 29% 25% 25% 25% 24% 24% 24% 0% 90 Top 5 Countries with the Highest M/S of RemsimaⓇSC 38% 37% 37% 35% 35% Germany 32% 34% Finland 25% 12% 20% 19% France 21% 17% 16% 15% 15% 15% 10% 14% Czech Republic 18% 44% 8% 12% 5% 4% 3% 2% 90 1% Belgium 12% 58% 0% 20.1Q 2Q 3Q 4Q 21.1Q 2Q 3Q 4Q 22.1Q 2Q 3Q 4Q RemsimaⓇ RemsimaⓇ SC Inflectra™ Note: The market share is based on the combined volume of 16 European countries RemsimaⓇSC has been launched Source: IQVIA, Market Data, etc. 29% 47% 0% 10% 20% 30% 40% 50% 60% 70% RemsimaⓇSC ■RemsimaⓇ & Inflectra™ Investor Relations 2023 7 1Q23 Business Results Key Products Plan & Vision Appendix

View entire presentation